Stay updated on Nivolumab vs. Everolimus in RCC: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.

Latest updates to the Nivolumab vs. Everolimus in RCC: Clinical Trial page
- Check7 days agoChange DetectedA site-wide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check14 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.1 to v3.7.2. The page still shows a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check21 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check35 days agoChange DetectedAccess to the study page is blocked, displaying a 403 Forbidden error. The page shows standard site chrome and a Home link, indicating the study record is not currently accessible.SummaryDifference0.5%

- Check42 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study content, effectively replacing the expected trial details with an access-denied message. This indicates an access issue that obscures the trial information and related navigation.SummaryDifference17%

- Check63 days agoChange DetectedA new revision label Revision: v3.6.6 appears on the page, replacing the previous Revision: v3.6.5. This indicates a site update/version change rather than a modification to the trial data or content.SummaryDifference0.0%

Stay in the know with updates to Nivolumab vs. Everolimus in RCC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs. Everolimus in RCC: Clinical Trial page.